Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 17,531 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Agent Clear all
Completed Phase 2 Interventional Results available

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

NCT03011034
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Talacotuzumab, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 28, 2026, 11:27 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Not applicable Interventional

Immune Activation and Drug Absorption in HIV-Infected Patients

NCT01845298
View directory record Official record
Conditions
HIV Infection
Interventions
Rifampicin 600 mg
Drug
Lead sponsor
Drexel University
Other
Eligibility
21 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 28, 2026, 11:27 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vivio AS (Aortic Stenosis) Algorithm Optimization Study

NCT04068402
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Vivio System
Device
Lead sponsor
Ventric Health, LLC
Industry
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps

NCT03280537
View directory record Official record
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Tucson, Arizona • Rancho Cordova, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

NCT03302845
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 28, 2026, 11:27 AM EDT
Terminated Phase 1Phase 2 Interventional

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

NCT00655395
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Laromustine (VNP40101M) and Ara-C
Drug
Lead sponsor
Viron Therapeutics Inc
Industry
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 28, 2026, 11:27 AM EDT
Not yet recruiting Phase 1 Interventional

Magnesium Sulfate in Pediatric Burn Dressing Changes

NCT07126795
View directory record Official record
Conditions
Pediatric Burns
Interventions
magnesium sulfate, Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Completed No phase listed Observational

Marijuana Drug Discrimination and Self-Administration

NCT00943930
View directory record Official record
Conditions
Marijuana Abuse
Interventions
THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 28, 2026, 11:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

NCT03838367
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenomics of Thiazolidinediones

NCT01135394
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
35 Years to 64 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 28, 2026, 11:27 AM EDT
Withdrawn Phase 2 Interventional

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

NCT04209556
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD, Placebo, PF-6826647 400 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
Canoga Park, California • Inglewood, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 28, 2026, 11:27 AM EDT
Not listed Not applicable Interventional

Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

NCT06171529
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
Interventions
CTM, Placebo
Device · Other
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer

NCT01851772
View directory record Official record
Conditions
Cervical Cancer
Interventions
Treatment with Electronic Brachytherapy
Device
Lead sponsor
Xoft, Inc.
Industry
Eligibility
Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 28, 2026, 11:27 AM EDT
Completed No phase listed Observational

Genetic Evaluation for Medication Selection (GEMS) Study

NCT03736057
View directory record Official record
Conditions
Dementia, Psychiatric Disorders Mood, Behavior Disorders
Interventions
Delayed results of pharmacogenomic results
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
40 participants
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 28, 2026, 11:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Not yet recruiting Phase 2 Interventional

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

NCT07765836
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
vilastobart (XTX101), Retifanlimab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Early Phase 1 Interventional

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

NCT04410237
View directory record Official record
Conditions
Psoriasis
Interventions
Med-Jet, Traditional Syringe
Device · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214 + citalopram, Placebo + citalopram
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Miami, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

NCT00229437
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
TAK-128, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
40
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 28, 2026, 11:27 AM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 28, 2026, 11:27 AM EDT
Recruiting Phase 3 Interventional

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245
View directory record Official record
Conditions
Patients With Non-Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, NGS HLAA2 assay
Drug · Device
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Beverly Hills, California • Encino, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

NCT00312377
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Interventions
Docetaxel, Vandetanib
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 28, 2026, 11:27 AM EDT